Small molecule · Agonist of progesterone receptor (PGR) · developed by Organon
Etonogestrel is a synthetic progestin, a form of the female sex hormone progesterone. It binds cytoplasmic progesterone receptors in the reproductive system, activating progesterone receptor-mediated gene expression, which inhibits luteinizing hormone release and ovulation and alters cervical mucus and the endometrium. It is studied in benign prostatic hyperplasia and menstrual symptoms.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 28, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00651807 | Phase 2 | Benign Prostatic Hyperplasia (BPH) | Terminated | OGN |
| NCT06775626 | Early Phase 1 | Menstrual Symptoms | Suspended | OGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Benign Prostatic Hyperplasia (BPH)Menstrual Symptoms
Updated Oct 25, 2026. Something wrong or missing? Report it on the OGN page.
See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OGN catalysts and pipeline →